It is recommended that female patients of childbearing potential or spouses of male patients undergo a pregnancy test (optional) before initiation of treatment with this product.
Female patients of childbearing potential or spouses of male patients should use effective contraceptive measures during treatment and for at least 180 days after the last dose;
Male patients of childbearing potential should also use effective contraceptive measures during treatment and for at least 180 days after the last dose.
